Multi-center, multiple-dose, randomized, double-blind, three-arm, placebo-controlled study of fixed-dose repeated oral dosing for 30 days of 10 mg and 30 mg MP-101 and placebo in obese subjects.

Inclusion Criteria:

• Subject is willing and able to provide signed informed consent.
• Subject is a male and is between 18-60 years of age.
• Subject is obese as defined as a BMI of 40 - 55.
• Subject is reasonably healthy and have a reasonably acceptable medical history
• Subject has a stable weight for the past 30 days per subject report.
• Subject who has at least one factor of the metabolic
• Subject exhibits stable behavior patterns with regard to smoking and exercise
• Subject can read, speak and write the English language and agrees to follow study procedures.

Exclusion Criteria:

• Subjects who have received any investigational medication within 3 months prior to administration of study drug
• Subjects with confirmed positive results of UDS or Alcohol
• Subjects who are unwilling to return to the clinical research center on specified days during the treatment periods.
• Subjects who have taken exclusionary medication
• Subjects with any clinically significant laboratory abnormality or illness which, in the opinion of the Investigator, would contraindicate study participation
• Subjects who have a history of testing positive for Hepatitis B virus, Hepatitis C virus, or HIV.
• Subject has been involved in a formal or informal (self-imposed) diet regimen within the last 30 days.
• Subject has a confirmed diagnosis or history of cancer, with the exception of nonmelanoma skin cancer.
• Subject is otherwise unsuitable for the study, in the opinion of the investigator.